IRVINE, CALIF. -- SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions.

The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering.

Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering.

The offering is being made pursuant to the Company’s effective shelf registration statement on Form S-3, including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”). The offering will be made only by means of a prospectus supplement filed with the SEC and the accompanying prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to the offering were filed with the SEC. Before you invest, you should read the preliminary prospectus supplement and the accompanying prospectus in their entirety and other documents the Company has filed with the SEC for more complete information about the Company and the offering. The preliminary prospectus supplement and the accompanying prospectus contain important, detailed information about the Company and the offering. You may also obtain these and the other documents referred to above, and the final prospectus supplement when available, for free by visiting the SEC’s website at www.sec.gov. Alternatively, copies of the preliminary prospectus supplement and accompanying prospectus, and the final prospectus supplement when available, may be obtained by contacting: Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, Attention: Syndicate Department, or by telephone at (212) 895-3745 or by email at syndicate@maximgrp.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.